Cogent Biosciences, Inc. COGT Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -85.7%-1.7pp | -73.7%+25.8pp | -95.4%-16.9pp | -107.6%-44.6pp | -84%-18.3pp | |
| Return on invested capital | -147.2%+25.0pp | -129.2%+9.1pp | -130%-19.4pp | -153.2%-46.0pp | -172.1%-24.3pp | |
| Liquidity | ||||||
| Current ratio | 15.1×+10.0× | 14.2×+8.9× | 6.4×-0.1× | 4.2×-5.1× | 5.1×-6.9× | |
| Leverage | ||||||
| Debt-to-equity | 0×-0.1× | 0×0.0× | 0.2×+0.1× | 0.4×+0.3× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $3.75+93.9% | $4.94+100% | $2.20-23.0% | $1.35-64.0% | $1.93-56.6% | |
| Valuation | ||||||
| Market capitalization | $6.25B+816% | $5.45B+533% | $2.01B+69.7% | $824.32M-10.6% | $681.96M+6.1% | |
| Price / book | 10.3×+7.2× | 8.6×+5.2× | 6.6×+2.9× | 5.3×+2.8× | 3.1×+1.6× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Cogent Biosciences, Inc.'s ratios come from?
- Every ratio is computed from Cogent Biosciences, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
